Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models. | Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers